Physician profile
Michael J Snyder
NPI 1477564839
$23,612.12
in general payments reported to CMS, 2019-2025
39 companies · $942 in 2025
The $942 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,320 · 2020: $4,104 · 2021: $3,636 · 2022: $1,841 · 2023: $5,883 · 2024: $887 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,997 · Food and Beverage: $2,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,996.87 |
| Food and Beverage | $2,714.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $11,937.81 | 2020-2024 | Gattex |
| Pacira Pharmaceuticals Incorporated | $3,673.43 | 2019-2025 | Exparel, Iovera |
| Covidien LP | $1,696.60 | 2019-2020 | |
| Thd America, INC. | $830.51 | 2019-2025 | |
| Medtronic, INC. | $759.93 | 2021-2025 | Signia, Interstim, Sonicision |
| Baxter Healthcare | $442.76 | 2021-2025 | Perclot, Tisseel |
| Ethicon US, LLC | $427.64 | 2019-2025 | Echelon Flex, Smartablatetm System Rf Generator |
| Davol INC. | $408.74 | 2019-2023 | Arista Ah Flexitip |
| Intuitive Surgical, INC. | $331.29 | 2022-2025 | |
| Tela Bio, INC. | $276.07 | 2021-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Shire North American Group INC | $261.24 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.60 | 2019-2024 | Xifaxan |
| Ferring Pharmaceuticals INC. | $232.42 | 2019-2022 | |
| Allergan, INC. | $225.27 | 2019-2020 | |
| Becton, Dickinson and Company | $202.25 | 2024 | Hemosphere |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.